MDT

86.28

+0.03%↑

114.91

+0.41%↑

VEEV

172.77

-0.08%↓

HQY

84.37

+1.03%↑

PHR.US

8.37

+0.48%↑

MDT

86.28

+0.03%↑

114.91

+0.41%↑

VEEV

172.77

-0.08%↓

HQY

84.37

+1.03%↑

PHR.US

8.37

+0.48%↑

MDT

86.28

+0.03%↑

114.91

+0.41%↑

VEEV

172.77

-0.08%↓

HQY

84.37

+1.03%↑

PHR.US

8.37

+0.48%↑

MDT

86.28

+0.03%↑

114.91

+0.41%↑

VEEV

172.77

-0.08%↓

HQY

84.37

+1.03%↑

PHR.US

8.37

+0.48%↑

MDT

86.28

+0.03%↑

114.91

+0.41%↑

VEEV

172.77

-0.08%↓

HQY

84.37

+1.03%↑

PHR.US

8.37

+0.48%↑

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Atvērts

SektorsVeselības aprūpe

4.62

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.42

Max

4.65

Galvenie mērījumi
By Trading Economics
Ienākumi	20M -7.9M
Pārdošana	4.1M 210M
Peļņas marža	-3.765
Darbinieki	2,700
EBITDA	-50M -60M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+46.22% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-11M 408M
Iepriekšējā atvēršanas cena	4.62
Iepriekšējā slēgšanas cena	4.62

Ziņu noskaņojums

By Acuity

50%

163 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

N/A / 7.55 Atbalsts un pretestība

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. apr. 22:56 UTC

Galvenie ziņu notikumi

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

2026. g. 1. apr. 20:50 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

2026. g. 1. apr. 23:55 UTC

Tirgus saruna

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

2026. g. 1. apr. 23:43 UTC

Tirgus saruna

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

2026. g. 1. apr. 23:23 UTC

Galvenie ziņu notikumi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

2026. g. 1. apr. 23:07 UTC

Peļņas

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

2026. g. 1. apr. 23:02 UTC

Galvenie ziņu notikumi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

2026. g. 1. apr. 22:39 UTC

Peļņas

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

2026. g. 1. apr. 22:08 UTC

Tirgus saruna

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

2026. g. 1. apr. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

2026. g. 1. apr. 21:31 UTC

Galvenie ziņu notikumi

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

2026. g. 1. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 1. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 1. apr. 20:38 UTC

Peļņas

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

2026. g. 1. apr. 20:31 UTC

Iegādes, apvienošanās, pārņemšana

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

2026. g. 1. apr. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

2026. g. 1. apr. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

2026. g. 1. apr. 20:13 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Extends Tender Offer To Acquire Arcellx >GILD

2026. g. 1. apr. 20:07 UTC

Tirgus saruna

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

2026. g. 1. apr. 20:07 UTC

Iegādes, apvienošanās, pārņemšana

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

46.22% augšup

Prognoze 12 mēnešiem

Vidējais 6.58 USD 46.22%

Augstākais 8.5 USD

Zemākais 4 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

N/A / 7.55Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

All events are bearish.

Noskaņojums

By Acuity

163 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.